Actively Recruiting
Phase III Study Comparing Adjuvant Radiotherapy with Sintilimab Versus TACE for Hepatocellular Carcinoma Patients After Surgery with Narrow Margins and High-Risk Features
Led by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Updated on 2025-09-22
286
Participants Needed
1
Research Sites
72 weeks
Total Duration
AI-Summary
What this Trial Is About
Researchers are conducting a phase III, open-label, randomized controlled trial to compare two treatments after surgery for hepatocellular carcinoma HCC with narrow surgical margins and high-risk features. The goal is to assess which approach better prevents cancer recurrence and improves survival over a two-year period. This multicenter study evaluates adjuvant radiotherapy combined with the drug sintilimab against transarterial chemoembolization TACE.
CONDITIONS
Brief Title
Adjuvant Radiotherapy of Sintilimab Versus TACE for HCC
Research Team
B
Bo Chen, MD.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
